Capital Deployment of approximately $670 million, including cash expected to be paid for frexalimab Development-stage portfolio growing to 15 therapies with potential significantly >$1 billion in peak royalties Financial guidance for full year 2024 (excludes contribution from future transactions) Exhibit 99.1 ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 20 ...

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma's development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalt ...

Investors are always looking for stocks that are poised to beat at earnings season and Royalty Pharma plc (RPRX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Royalty Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty ...

The upcoming report from Royalty Pharma (RPRX) is expected to reveal quarterly earnings of $0.96 per share, indicating a decline of 40% compared to the year-ago period. Analysts forecast revenues of $671.45 million, representing a decrease of 40.6% year over year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collabora ...

Royalty Pharma (RPRX) reported $736 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 30.8%. EPS of $1.15 for the same period compares to $1.56 a year ago.The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Financial Data and Key Metrics Changes - The company reported a 9% growth in portfolio receipts for 2023, with royalty receipts increasing by 8% [30][42] - The fourth quarter saw a 10% growth in royalty receipts, contributing to the overall positive momentum [32][49] - The company achieved $4 billion in announced transactions and $2.2 billion in actual cash deployed during the year, marking a record for synthetic royalty transactions [30][31][36] Business Line Data and Key Metrics Changes - Synthetic royalties, which have historically been a small part of funding, are expected to grow rapidly, with nearly $800 million in transactions recorded in 2023, doubling since the IPO [3][36] - The company added royalties on eight therapies in 2023, including incremental royalties on the blockbuster therapy Evrysdi [30][32] Market Data and Key Metrics Changes - The royalty market saw $7.4 billion in announced transactions in 2023, representing the strongest year ever for royalty funding, with the company maintaining a 53% market share [2] - The company has significantly broadened its portfolio through approximately $13 billion of transactions announced since 2020, exceeding initial guidance [32] Company Strategy and Development Direction - The company aims to be the leading partner funding innovation in life sciences, focusing on acquiring attractive long-duration royalties [30][54] - Management emphasizes the importance of maintaining a disciplined approach to capital allocation, prioritizing new royalty investments over share buybacks [14][54] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering top-line growth with a compound annual growth rate (CAGR) of 10% or more over the decade, despite potential headwinds from product switches and biosimilars [7][30] - The company expects portfolio receipts for 2024 to be between $2.6 billion and $2.7 billion, reflecting underlying growth from its portfolio [31][50] Other Important Information - The company has made changes to its financial presentation to enhance transparency, introducing new non-GAAP measures such as portfolio cash flow and capital deployment [47][48] - The company maintains significant financial capacity for future royalty acquisitions, with over $3.55 billion available through cash and debt markets [44] Q&A Session All Questions and Answers Question: What are the next steps in the dispute regarding royalty levels? - Management indicated there are no updates on the dispute with Vertex and will provide information as it becomes available [7] Question: Can you elaborate on the market for synthetic royalties and their returns compared to traditional structures? - Management noted that synthetic royalties are gaining traction and historically have provided higher returns than traditional royalty structures [62] Question: Should the $4 billion in transactions be considered a new norm for Royalty Pharma? - Management clarified that while there is strong momentum, they are not changing their long-term capital deployment guidance of $10 billion to $12 billion over five years [64] Question: How does the company view the turnover in the shareholder base? - Management aims to focus on long-term holders and educate new investors about the unique aspects of the business [76] Question: What is the company's stance on the Tysabri biosimilar? - Management is monitoring the situation and believes Tysabri will continue to have significant sales despite potential competition from biosimilars [73]

| --- | --- | --- | --- | |-------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | 1 1 | | 3 | 4 | | Financial | Portfolio | Capital allocation | Full-year guidance | | Strong portfolio growth, including the CF franchise, Trelegy, Tremfya a ...

Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced transactions of up to $4.0 billion in 2023Full year 2024 guidance: Portfolio Receipts of $2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR For the transition period from _________ to __________ Commission file number 001-39329 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (St ...